The National Institute on Aging offers funding for the development of small-molecule and biologic therapeutic agents aimed at preventing, slowing the progression, or treating the cognitive and behavioral symptoms of Alzheimer’s disease. This grant supports activities including medicinal chemistry, PK, ADMET, animal model efficacy studies, GMP chemical synthesis, IND enabling studies, and initial Phase I clinical testing. Not open to research on disease mechanisms, biomarkers, devices, non-pharmacological interventions, repurposed drugs, combination therapies, high throughput screening, or hit optimization. Closing date for applications is June 7, 2018.
Opportunity ID: 298554
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-18-174 |
| Funding Opportunity Title: | Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Nov 08, 2017 |
| Last Updated Date: | Jun 07, 2018 |
| Original Closing Date for Applications: | May 07, 2018 |
| Current Closing Date for Applications: | Jun 07, 2018 |
| Archive Date: | Jul 07, 2018 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Small businesses City or township governments Special district governments State governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Private institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development ofsmall-molecule and biologic therapeutic agents that prevent Alzheimer’s disease (AD), slow its progression or treat its cognitive and behavioral symptoms.Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-18-174.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Expired and Re-issued as PAR-18-820 | Jun 07, 2018 | |
| Updated Expiration Date in accordance with the notice NOT-AG-18-002 | Jun 07, 2018 | |
| Feb 01, 2018 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-18-174 |
| Funding Opportunity Title: | Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Nov 08, 2017 |
| Last Updated Date: | Jun 07, 2018 |
| Original Closing Date for Applications: | May 07, 2018 |
| Current Closing Date for Applications: | Jun 07, 2018 |
| Archive Date: | Jul 07, 2018 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Small businesses City or township governments Special district governments State governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Private institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development ofsmall-molecule and biologic therapeutic agents that prevent Alzheimer’s disease (AD), slow its progression or treat its cognitive and behavioral symptoms.Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-18-174.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-18-174 |
| Funding Opportunity Title: | Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jun 07, 2018 |
| Last Updated Date: | Feb 01, 2018 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 07, 2018 |
| Archive Date: | Oct 07, 2018 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Private institutions of higher education Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education County governments Independent school districts Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments For profit organizations other than small businesses State governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development ofsmall-molecule and biologic therapeutic agents that prevent Alzheimer’s disease (AD), slow its progression or treat its cognitive and behavioral symptoms.Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-18-174.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-18-174 |
| Funding Opportunity Title: | Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 01, 2018 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | May 07, 2018 |
| Archive Date: | Jun 12, 2018 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Private institutions of higher education Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education County governments Independent school districts Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments For profit organizations other than small businesses State governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development ofsmall-molecule and biologic therapeutic agents that prevent Alzheimer’s disease (AD), slow its progression or treat its cognitive and behavioral symptoms.Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-18-174.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | Use for due dates on or after January 25, 2018 | PKG00235973 | Jan 06, 2018 | Jun 08, 2018 | View |
Package 1
Mandatory forms
298554 RR_SF424_2_0-2.0.pdf
298554 PHS398_CoverPageSupplement_4_0-4.0.pdf
298554 RR_OtherProjectInfo_1_4-1.4.pdf
298554 PerformanceSite_2_0-2.0.pdf
298554 RR_KeyPersonExpanded_2_0-2.0.pdf
298554 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
298554 RR_Budget_1_4-1.4.pdf
298554 RR_SubawardBudget30_1_4-1.4.pdf
298554 PHS398_ModularBudget_1_2-1.2.pdf
298554 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
